Differential responses to immune checkpoint inhibitors are governed by diverse mismatch repair gene alterations.
Moh'd M KhushmanMichael D ToboniJoanne XiuUpender ManneAlex P FarrellEmil LouAnthony Frank ShieldsPhilip A PhilipMohamed E SalemJim AbrahamDavid B SpetzlerJohn L MarshallPriya JayachandranMichael J HallHeinz-Josef LenzIbrahim Halil SahinAndreas SeeberMatthew A PowellPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Patients with mutS co-loss experienced longer mOS in CRC and EC and better response to ICIs in CRC. Among all explored biomarkers, NAL was higher in mutS co-loss and may be a potential driving factor for the observed better outcomes. TMB did not reliably predict NAL.